Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald, R., Kleeberg, U., 2005.

Oncology 68, 326–32. doi:10.1159/000086971

Studie: BUC-37/CID; Indikation: Kolorektalkarzinom; Jahr: 2005; Veranstaltung: -; Journal: Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com